Background: Viral hepatitis C is a major public health problem in the world. The advent of direct-acting antivirals has revolutionized the taking in charge and prognosis of patients infected with the hepatitis C virus. The interest of this presentation is to draw attention to the problem of therapeutic care posed by viral hepatitis C in kidney transplant patients in Côte d'Ivoire, a country with limited resources where all direct-acting antivirals are not yet available. Patient observation: We report the case of a kidney transplant of 52 years old, chronic bearer of viral hepatitis C virus who after his kidney transplant presented, decompensated active cirrhosis. A treatment based on Sofosbuvir 400 mg/Ledipasvir 90 mg in this patient with genotype 2 for 12 weeks was initiated. A sustained virological response was observed 12 weeks after the end of treatment. Conclusion: Direct-acting antivirals offer the possibility of antiviral C treatment without interferon or ribavirin in cirrhotic renal transplant.
Introduction
Hepatitis C virus (HCV) infection affects more than 200 million people world- wide and its prevalence is high in patients with end-stage renal disease thus increasing challenges in renal transplant patients infected with HCV. In developed countries around 1.8% to 8% of renal transplant patients are infected with HCV [1] . Despite recent therapeutic advances, the treatment of HCV infection remains a challenge. The arrival of new direct-acting antivirals (DAAs) is a revolution for the treatment of HCV infection and particularly in kidney transplant [2] . In Côte d'Ivoire, a country with limited resources, only a few therapeutic classes of DAAs are available. We report the case of a kidney transplant patient, chronic HCV bearer who presented after his kidney transplant, an array of decompensated cirrhosis in a context of deterioration in general condition and high viral load. The provision of Sofosbuvir/Ledipasvir in Côte d'Ivoire has made it possible to initiate treatment in this patient. All information gathered in this study was processed in accordance with the Code of Ethics. The patient has given his consent regarding this case report.
Patient and Observation
A 52-year-old married man residing in Abidjan was hospitalized for general im- 
Discussion

Epidemiology
Chronic infection with HVC is the most common cause of liver diseases after 
HCV Viral Load and Liver Fibrosis
We do not have values of HCV viral load and information on liver fibrosis before kidney transplant, but probably he would have had relatively lower hepatic fibrosis and viral load for transplant, compared to viral load and fibrosis after kidney transplant. In the literature, it has been shown a significant increase in HCV viremia a year after the introduction of immunosuppressive treatment with Mycophenolate mofetil [4] . Corticosteroids are also responsible for an increase in viral replication and more rapid progression to cirrhosis in immunocompetent subject [5] . After kidney transplant, there is a rise in serum concentration of HCV RNA which is probably due to the decrease of the immune response under immunosuppressive therapy, and for the establishment of a new balance between the production of virions and their clearance [3] [6] [7] [8].
Influence of HCV on the Renal Graft Survival
In our case, we observed normal kidney function and an absence of proteinuria six years after kidney transplant. Hestin et al. [9] showed that the presence of anti-HCV antibodies before kidney transplantation was predictive of the appearance of proteinuria after transplantation and graft survival of patients infected with HCV and proteinuric is less than that of non-proteinuria patients. Cosio et al. [10] reported that HCV-infected kidney transplants have a high prevalence of acute or chronic vascular rejection in the first six months after transplantation, resulting in decreased graft survival. Conversely, other authors have reported a lower rate of acute rejection in kidney transplant patients with HCV compared to kidney transplant patients not infected with HCV [11] . This reduction in graft survival seems to be due to the appearance of glomerular diseases attributable to the virus [11] . Recently, it has been shown that in HCV + kidney transplant patients with de novo glomerular diseases, the occurrence of these glomerular was not related to either an increase in the serum HCV RNA concentration after transplantation, nor to an effect describes the virus on kidney cells, but rather to a change in the immune response [7] .
Combination Sofosbuvir/Ledipasvir and HCV Genotype 2
There are no major studies evaluating the combination Sofosbuvir/Ledipasvir in HCV infected patients with HCV genotype 2 and Ledipasvir has a low activity on HCV genotype [12] . We did not find in the literature a study evaluating the combination sofosbuvir/ledipasvir in kidney transplant patients infected with HCV genotype 2.
However a rapid virologic response was observed in 22 of 25 patients (88%) in the series Kamar et al. [15] ; they also found that at the end of treatment, HCV RNA was undetectable in all patients. 4 to 12 weeks after therapy with DAAs, all patients had a sustained virologic response and normalization of transaminases.
Tolerance to anti-HCV therapy was excellent and no adverse effects were observed. They therefore concluded that the DAAs are effective and safe for treating HCV infection after kidney transplantation.
Conclusion
Hepatitis C in the kidney transplant is common. Here we report the efficacy of the Sofosbuvir/Ledipasvir combination in a genotype 2 positive HCV patient.
This is the first case diagnosed in black francophone Africa. The evolution was favorable with a sustained viral response 12 weeks after the end of treatment.
The hope of accessible treatment and affordable is therefore possible in black Africa for HCV positive hemodialysis patients as well as HCV positive kidney transplant patients.
